Maynard Um
-
-
-
-
-
-
-
Bernstein SocGen Group Resumes Natera (NTRA) at Outperform
-
-
-
-
-
-
-
Goldman Sachs Starts Natera (NTRA) at Neutral
-
-
-
-
-
-
-
FDA approves Natera's Signatera CDx for bladder cancer treatment decisions
-
-
-
-
-
-
-
Citi Adjusts Catalyst Watch List
-
-
-
-
-
-
-
Natera submits bladder cancer diagnostic test to FDA for approval
-
-
-
-
-
-
-
Citi Starts Natera (NTRA) at Buy
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
432,729 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

